Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Intensive Hemodialysis and Treatment Complications and Tolerability
Jose A. Morfin
, Richard J. Fluck
, Eric D. Weinhandl
, Sheru Kansal
, Peter A. McCullough
, Paul Komenda
Administration (AHS)
Research output
:
Contribution to journal
›
Article
›
peer-review
76
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Intensive Hemodialysis and Treatment Complications and Tolerability'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Recovery Time
100%
Intensive Treatment
100%
Hemodialysis Complications
100%
Treatment Complications
100%
Maintenance Hemodialysis
100%
Intradialytic Hypotension
85%
Hemodialysis
71%
Hospitalization
28%
Ultrafiltration
28%
Dialysis Efficiency
28%
Short Daily
28%
Myocardial Stunning
28%
Tolerability
14%
Risk Reduction
14%
Patient-centered
14%
Dialysis
14%
Blood Pressure
14%
End-stage Renal Disease
14%
Prospective Cohort Study
14%
Practice Patterns
14%
Ventricular Arrhythmia
14%
Hemodialysis Patients
14%
Systolic Blood Pressure
14%
Common Complications
14%
Blood Pressure Variability
14%
Interdialytic Weight Gain
14%
Frequent Hemodialysis Network
14%
Ultrafiltration Volume
14%
Intradialytic Hypertension
14%
Nocturnal Hemodialysis
14%
Outcome Patterns
14%
Per-protocol Analysis
14%
Treatment Sessions
14%
Nursing and Health Professions
Hemodialysis
100%
Hypotension
46%
Ultrafiltration
23%
Stunned Heart Muscle
15%
Heart Arrhythmia
7%
Blood Pressure
7%
Outcome Assessment
7%
Systolic Blood Pressure
7%
Prospective Cohort Study
7%
End Stage Renal Disease
7%
Blood Pressure Variability
7%
Emotions
7%
Cross-Sectional Study
7%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
100%
Hypotension
46%
Stunned Heart Muscle
15%
Tolerability
7%
Prospective Cohort Study
7%
Heart Arrhythmia
7%
End Stage Renal Disease
7%
Cross-Sectional Study
7%